QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:TRVN

Trevena (TRVN) Stock Forecast, Price & News

$1.10
+0.02 (+1.85%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.04
$1.11
50-Day Range
$0.61
$3.11
52-Week Range
$0.58
$12.22
Volume
386,269 shs
Average Volume
1.71 million shs
Market Capitalization
$12.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Trevena MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$5.50 Price Target
Short Interest
Bearish
7.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Trevena in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.90) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

575th out of 981 stocks

Pharmaceutical Preparations Industry

266th out of 464 stocks


TRVN stock logo

About Trevena (NASDAQ:TRVN) Stock

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Stock News Headlines

StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Trevena Achieves Listing Compliance On Nasdaq
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Trevena (NASDAQ:TRVN) Issues Quarterly Earnings Results
JMP Securities Sticks to Their Buy Rating for Trevena (TRVN)
Trevena (TRVN) to Release Earnings on Monday
Trevena Earnings Preview
Trevena Q1 Earnings Preview
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com
JMP Securities Keeps Their Buy Rating on Trevena (TRVN)
See More Headlines

TRVN Price History

TRVN Company Calendar

Last Earnings
5/15/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+406.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$2.25 per share

Miscellaneous

Free Float
10,607,000
Market Cap
$11.90 million
Optionable
Optionable
Beta
2.02

Key Executives

  • Carrie L. BourdowCarrie L. Bourdow
    President, Chief Executive Officer & Director
  • Barry Shin
    Chief Financial Officer & Senior Vice President
  • Mark A. Demitrack
    Chief Medical Officer & Senior Vice President
  • Angela Bagley
    Vice President-Technical Operations
  • Todd L. Wandstrat
    Vice President-Medical Affairs













TRVN Stock - Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings
or view top-rated stocks.

What is Trevena's stock price forecast for 2023?

2 brokers have issued 12-month target prices for Trevena's stock. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 406.9% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2023?

Trevena's stock was trading at $1.43 at the start of the year. Since then, TRVN stock has decreased by 24.1% and is now trading at $1.0850.
View the best growth stocks for 2023 here
.

Are investors shorting Trevena?

Trevena saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 752,700 shares, an increase of 341.2% from the April 30th total of 170,600 shares. Based on an average daily volume of 2,500,000 shares, the short-interest ratio is currently 0.3 days. Approximately 7.1% of the company's shares are short sold.
View Trevena's Short Interest
.

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our TRVN earnings forecast
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The biopharmaceutical company earned $0.01 million during the quarter, compared to the consensus estimate of $0.60 million. During the same period last year, the firm earned ($2.50) earnings per share.

When did Trevena's stock split?

Trevena shares reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?
What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (3.42%), Renaissance Technologies LLC (0.74%), Jane Street Group LLC (0.47%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends
.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.09.

How much money does Trevena make?

Trevena (NASDAQ:TRVN) has a market capitalization of $11.90 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($6.04) on an earnings per share basis.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.

This page (NASDAQ:TRVN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -